The solute carrier transporters and the brain: Physiological and pharmacological implications
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Solute carriers (SLCs) are the largest family of transmembrane transporters that determine the exchange of various substances, including nutrients, ions, metabolites, and drugs across biological membranes. To date, the presence of about 287 SLC genes have been identified in the brain, among which mutations or the resultant dysfunctions of 71 SLC genes have been reported to be correlated with human brain disorders. Although increasing interest in SLCs have focused on drug development, SLCs are currently still under-explored as drug targets, especially in the brain. We summarize the main substrates and functions of SLCs that are expressed in the brain, with an emphasis on selected SLCs that are important physiologically, pathologically, and pharmacologically in the blood-brain barrier, astrocytes, and neurons. Evidence suggests that a fraction of SLCs are regulated along with the occurrences of brain disorders, among which epilepsy, neurodegenerative diseases, and autism are representative. Given the review of SLCs involved in the onset and procession of brain disorders, we hope these SLCs will be screened as promising drug targets to improve drug delivery to the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O'Keeffe, S., Phatnani, H. P., Guarnieri, P., Caneda, C., Ruderisch, N., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1860-14.2014 · Cited by 4,875
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Brain energy metabolism: focus on Astrocyte-neuron metabolic cooperation
Bélanger, M., Allaman, I., & Magistretti, P. J. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.08.016 · Cited by 2,313
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Astrocyte-Neuron Lactate Transport Is Required for Long-Term Memory Formation
Suzuki, A., Stern, S. A., Bozdagi, O., Huntley, G. W., Walker, R. H., Magistretti, P. J., & Alberini, C. M. (2011) · Cell · doi:10.1016/j.cell.2011.02.018 · Cited by 1,711
A Cellular Perspective on Brain Energy Metabolism and Functional Imaging
Magistretti, P. J., & Allaman, I. (2015) · Neuron · doi:10.1016/j.neuron.2015.03.035 · Cited by 1,285
Duman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026
Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity.
Sibson, N. R., Dhankhar, A., Mason, G. F., Rothman, D. L., Behar, K. L., & Shulman, R. G. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.316 · Cited by 897
Mechanistic diversity in ATP-binding cassette (ABC) transporters.
Locher, K. P. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3216 · Cited by 804
Deficient glutamate tranport is associated with neurodegeneration in Alzheimer's disease
Masliah, E., Hansen, L., Alford, M., Deteresa, R., & Mallory, M. (1996) · Annals of Neurology · doi:10.1002/ana.410400512 · Cited by 476
Jacob, C. P., Koutsilieri, E., Bartl, J., Neuen-Jacob, E., Arzberger, T., Zander, N., Ravid, R., Roggendorf, W., Riederer, P., & Grünblatt, E. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-11113 · Cited by 317
The 4F2hc/LAT1 complex transports l-DOPA across the blood–brain barrier
Kageyama, T., Nakamura, M., Matsuo, A., Yamasaki, Y., Takakura, Y., Hashida, M., Kanai, Y., Naito, M., Tsuruo, T., Minato, N., et al. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02758-x · Cited by 298
Glucose Transporters in Brain: In Health and in Alzheimer’s Disease
Szablewski, L. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160841 · Cited by 211 · cited 12×
“SLCs function in energy metabolism he energy demands of the brain are very high and glucose s the obligatory energy substrate of the adult brain [57 ,58] . lucose is a polar, hydrophilic molecule that is transported argely via the glucose transporter SLC2A [59] .”
BackgroundInfluentialJha, M. K., & Morrison, B. M. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.07.009 · Cited by 203
Pardridge, W. M. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1042364 · Cited by 159 · cited 1×
“Pardridge (2015) introduced a high throughput creening of a small molecule neuropharmaceutical library or drugs interacting with SLCs expressed in the BBB [129] , n which a mammalian host cell line overexpressing SLC ransporters was used to screen small molecule libraries. ashima reviewed…”
MethodBoulland, J.-L., Jenstad, M., Boekel, A. J., Wouterlood, F. G., Edwards, R. H., Storm-Mathisen, J., & Chaudhry, F. A. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn077 · Cited by 107
Presynaptic control of inhibitory neurotransmitter content in VIAAT containing synaptic vesicles
Aubrey, K. R. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.06.002 · Cited by 30 · cited 1×
“erminals [43] ; SLC32A1 is expressed in GABAergic neurons nd mediates the uptake of GABA and glycine into the ynaptic vesicles [44] .”
Background
Research works printed but not linked: 125
- Hediger, 2013, The ABCs of membrane transporters in health and disease (SLC series): introduction, Mol Aspects Med, 34, 95, 10.1016/j.mam.2012.12.009 · DOI · Paper page
- Zhang, 2019, The SLC transporter in nutrient and metabolic sensing, regulation, and drug development, J Mol Cell Biol., 11, 1, 10.1093/jmcb/mjy052 · DOI · Paper page
- Cesar-Razquin, 2015, A call for systematic research on solute carriers, Cell, 162, 478, 10.1016/j.cell.2015.07.022 · DOI · Paper page
- Song, 2019, Organic cation transporter 3 (Oct3) is a distinct catecholamines clearance route in adipocytes mediating the beiging of white adipose tissue, PLoS Biol, 17, 10.1371/journal.pbio.2006571 · DOI
- Hall, 2019, l-Type amino acid transporter 1 activity of 1,2,3-triazolyl analogs of l-histidine and l-tryptophan, Bioorg Med Chem Lett;, 10.1016/j.bmcl.2019.06.033 · DOI
- Guan, 2018, Elevated na/h exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas, J Exp Clin Cancer Res, 37, 255, 10.1186/s13046-018-0923-z · DOI
- Li, 2018, Subcellular drug distribution: mechanisms and roles in drug efficacy, toxicity, resistance, and targeted delivery, Drug Metab Rev, 50, 430, 10.1080/03602532.2018.1512614 · DOI
- LeVine, 2016, Allosteric mechanisms of molecular machines at the membrane: transport by sodium-coupled symporters, Chem Rev, 116, 6552, 10.1021/acs.chemrev.5b00627 · DOI
- Cocucci, 2017, Role of passive diffusion, transporters, and membrane trafficking-mediated processes in cellular drug transport, Clin Pharmacol Ther, 101, 121, 10.1002/cpt.545 · DOI
- Hossain, 2019, General and specific interactions of the phospholipid bilayer with P-type ATPases, Biophys Rev, 11, 353, 10.1007/s12551-019-00533-2 · DOI
- Drew, 2016, Shared molecular mechanisms of membrane transporters, Annu Rev Biochem, 85, 543, 10.1146/annurev-biochem-060815-014520 · DOI · Paper page
- Takahashi, 2015, Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease, Cell Mol Life Sci, 72, 3489, 10.1007/s00018-015-1937-8 · DOI · Paper page
- Perland, 2017, Classification systems of secondary active transporters, Trends Pharmacol Sci, 38, 305, 10.1016/j.tips.2016.11.008 · DOI · Paper page
- Counillon, 2016, Na(+)/H(+) antiporter (NHE1) and lactate/H(+) symporters (MCTs) in pH homeostasis and cancer metabolism, Biochim Biophys Acta, 1863, 2465, 10.1016/j.bbamcr.2016.02.018 · DOI
- Rask-Andersen, 2013, Solute carriers as drug targets: current use, clinical trials and prospective, Mol Aspects Med, 34, 702, 10.1016/j.mam.2012.07.015 · DOI
- Brzica, 2017, Role of transporters in central nervous system drug delivery and blood-brain barrier protection: relevance to treatment of stroke, J Cent Nerv Syst Dis, 9, 10.1177/1179573517693802 · DOI · Paper page
- Turkova, 2019, Current advances in studying clinically relevant transporters of the solute carrier (SLC) family by connecting computational modeling and data science, Comput Struct Biotechnol J, 17, 390, 10.1016/j.csbj.2019.03.002 · DOI
- Al-Abdulla, 2019, Unraveling 'the cancer genome atlas' information on the role of SLC transporters in anticancer drug uptake, Expert Rev Clin Pharmacol, 12, 329, 10.1080/17512433.2019.1581605 · DOI
- Liang, 2015, The physiological role of drug transporters, Protein Cell, 6, 334, 10.1007/s13238-015-0148-2 · DOI
- Chen, 2019, Regulation of glucose and lipid metabolism in health and disease, Sci China Life Sci, 62, 1420, 10.1007/s11427-019-1563-3 · DOI · Paper page
- Spencer, 2018, Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier, J Neurol Neurosurg Psychiatry, 89, 42, 10.1136/jnnp-2017-316011 · DOI · Paper page
- Lee, 2017, Hypoxic-ischaemic encephalopathy and the blood-brain barrier in beonates, Dev Neurosci, 39, 49, 10.1159/000467392 · DOI
- Wong, 2019, Review of current strategies for delivering alzheimer's disease drugs across the blood-brain barrier, Int J Mol Sci, 20, E381, 10.3390/ijms20020381 · DOI · Paper page
- Dadas, 2019, Breakdown of blood brain barrier as a mechanism of post-traumatic epilepsy, Neurobiol Dis, 123, 20, 10.1016/j.nbd.2018.06.022 · DOI · Paper page
- Nalecz, 2017, Solute carriers in the blood-brain barier: safety in abundance, Neurochem Res, 42, 795, 10.1007/s11064-016-2030-x · DOI
- Puris, 2019, Mechanistic study on the use of the l-type amino acid transporter 1 for brain intracellular delivery of ketoprofen via prodrug: a novel approach supporting the development of prodrugs for intracellular targets, Mol Pharm;, 16, 3261, 10.1021/acs.molpharmaceut.9b00502 · DOI
- Abdullahi, 2018, Functional expression of organic anion transporting polypeptide 1a4 is regulated by transforming growth factor-beta/activin receptor-like kinase 1 signaling at the blood-brain barrier, Mol Pharmacol, 94, 1321, 10.1124/mol.118.112912 · DOI
- Kou, 2018, Recent advances in drug delivery via the organic cation/carnitine transporter 2 (OCTN2/SLC22A5), Expert Opin Ther Targets, 22, 715, 10.1080/14728222.2018.1502273 · DOI · Paper page
- Ferreira, 2017, l-carnitine and acetyl-l-carnitine roles and neuroprotection in developing brain, Neurochem Res, 42, 1661, 10.1007/s11064-017-2288-7 · DOI · Paper page
- Napolitano, 2009, Carnitine conjugate of nipecotic acid: a new example of dual prodrug, Molecules, 14, 3268, 10.3390/molecules14093268 · doi:10.3390/molecules14093268
- Kou, 2018, l-Carnitine-conjugated nanoparticles to promote permeation across blood-brain barrier and to target glioma cells for drug delivery via the novel organic cation/carnitine transporter OCTN2, Artif Cells Nanomed Biotechnol, 46, 1605
- Ronaldson, 2013, Targeted drug delivery to treat pain and cerebral hypoxia, Pharmacol Rev, 65, 291, 10.1124/pr.112.005991 · DOI
- Ronaldson, 2011, Inflammatory pain signals an increase in functional expression of organic anion transporting polypeptide 1a4 at the blood-brain barrier, J Pharmacol Exp Ther, 336, 827, 10.1124/jpet.110.174151 · DOI
- Ho, 2012, Expression profiling of solute carrier gene families at the blood-CSF barrier, Front Pharmacol, 3, 154, 10.3389/fphar.2012.00154 · DOI · Paper page
- Furihata, 2017, Functional expression of organic ion transporters in astrocytes and their potential as a drug target in the treatment of central nervous system diseases, Biol Pharm Bull, 40, 1153, 10.1248/bpb.b17-00076 · DOI
- Ashraf, 2014, Functional expression of drug transporters in glial cells: potential role on drug delivery to the CNS, Adv Pharmacol, 71, 45, 10.1016/bs.apha.2014.06.010 · DOI
- Duan, 2010, Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3, J Pharmacol Exp Ther, 335, 743, 10.1124/jpet.110.170142 · DOI · Paper page
- Takahashi, 2015, Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for alzheimer's disease, J Exp Med, 212, 319, 10.1084/jem.20140413 · DOI · Paper page
- Pajarillo, 2019, The role of astrocytic glutamate transporters GLT-1 and glast in neurological disorders: potential targets for neurotherapeutics, Neuropharmacology, 165
- Sery, 2015, GLAST but not least–distribution, function, genetics and epigenetics of l-glutamate transport in brain–focus on GLAST/EAAT1, Neurochem Res, 40, 2461, 10.1007/s11064-015-1605-2 · DOI
- Zhang, 2018, Vesicular glutamate transporter isoforms: the essential players in the somatosensory systems, Prog Neurobiol, 171, 72, 10.1016/j.pneurobio.2018.09.006 · DOI
- Zander, 2010, Synaptic and vesicular coexistence of vglut and vgat in selected excitatory and inhibitory synapses, J Neurosci, 30, 7634, 10.1523/JNEUROSCI.0141-10.2010 · DOI · Paper page
- Tordera, 2007, Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1), Eur J Neurosci, 25, 281, 10.1111/j.1460-9568.2006.05259.x · DOI · Paper page
- Janickova, 2017, Vesicular acetylcholine transporter (VAChT) over-expression induces major modifications of striatal cholinergic interneuron morphology and function, J Neurochem, 142, 857, 10.1111/jnc.14105 · DOI
- Padua-Reis, 2017, Reduced vesicular acetylcholine transporter favors antidepressant behaviors and modulates serotonin and dopamine in female mouse brain, Behav Brain Res, 330, 127, 10.1016/j.bbr.2017.04.049 · DOI
- Pramod, 2013, SLC6 transporters: structure, function, regulation, disease association and therapeutics, Mol Aspects Med, 34, 197, 10.1016/j.mam.2012.07.002 · DOI · Paper page
- Rudnick, 2014, The SLC6 transporters: perspectives on structure, functions, regulation, and models for transporter dysfunction, Pflugers Arch, 466, 25, 10.1007/s00424-013-1410-1 · DOI · Paper page
- Salatino-Oliveira, 2018, The dopamine transporter role in psychiatric phenotypes, Am J Med Genet B Neuropsychiatr Genet, 177, 211, 10.1002/ajmg.b.32578 · DOI
- Efimova, 2016, Dopamine transporter mutant animals: a translational perspective, J Neurogenet, 30, 5, 10.3109/01677063.2016.1144751 · DOI
- Traiffort, 2013, The choline transporter-like family SLC44: properties and roles in human diseases, Mol Aspects Med, 34, 646, 10.1016/j.mam.2012.10.011 · DOI
- Wang, 2019, Glucose transporter 1 critically controls microglial activation through facilitating glycolysis, Mol Neurodegener, 14, 2, 10.1186/s13024-019-0305-9 · DOI · Paper page
- Castellotti, 2019, Screening of SLC2A1 in a large cohort of patients suspected for Glut1 deficiency syndrome: identification of novel variants and associated phenotypes, J Neurol, 266, 1439, 10.1007/s00415-019-09280-6 · DOI
- Espinoza-Rojo, 2010, Glucose transporters regulation on ischemic brain: possible role as therapeutic target, Cent Nerv Syst Agents Med Chem, 10, 317, 10.2174/187152410793429755 · doi:10.2174/187152410793429755
- Koch, 2019, The glucose transporter type 1 (Glut1) syndromes, Epilepsy Behav, 91, 90, 10.1016/j.yebeh.2018.06.010 · DOI
- Sonnay, 2018, Astrocytic and neuronal oxidative metabolism are coupled to the rate of glutamate-glutamine cycle in the tree shrew visual cortex, Glia, 66, 477, 10.1002/glia.23259 · DOI · Paper page
- Dienel, 2019, Does shuttling of glycogen-derived lactate from astrocytes to neurons take place during neurotransmission and memory consolidation?, J Neurosci Res, 97, 863, 10.1002/jnr.24387 · DOI · Paper page
- Broer, 2001, Transfer of glutamine between astrocytes and neurons, J Neurochem, 77, 705, 10.1046/j.1471-4159.2001.00322.x · DOI · Paper page
- Leke, 2016, The glutamine transporters and their role in the glutamate/GABA-glutamine cycle, Adv Neurobiol, 13, 223, 10.1007/978-3-319-45096-4_8 · DOI
- Jenstad, 2013, The amino acid transporters of the glutamate/GABA-glutamine cycle and their impact on insulin and glucagon secretion, Front Endocrinol (Lausanne), 4, 199, 10.3389/fendo.2013.00199 · DOI
- Gliddon, 2009, Cellular distribution of the neutral amino acid transporter subtype ASCT2 in mouse brain, J Neurochem, 108, 372, 10.1111/j.1471-4159.2008.05767.x · DOI · Paper page
- Omote, 2016, Structure, function, and drug interactions of neurotransmitter transporters in the postgenomic era, Annu Rev Pharmacol Toxicol, 56, 385, 10.1146/annurev-pharmtox-010814-124816 · DOI
- Gasnier, 2004, The SLC32 transporter, a key protein for the synaptic release of inhibitory amino acids, Pflugers Arch, 447, 756, 10.1007/s00424-003-1091-2 · DOI
- Lawal, 2013, SLC18: vesicular neurotransmitter transporters for monoamines and acetylcholine, Mol Aspects Med, 34, 360, 10.1016/j.mam.2012.07.005 · DOI · Paper page
- Eiden, 2004, The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine, Pflugers Arch, 447, 636, 10.1007/s00424-003-1100-5 · DOI · Paper page
- Morris, 2017, SLC and abc transporters: expression, localization, and species differences at the blood-brain and the blood-cerebrospinal fluid barriers, AAPS J, 19, 1317, 10.1208/s12248-017-0110-8 · DOI · Paper page
- Abdullahi, 2017, Functional expression of P-glycoprotein and organic anion transporting polypeptides at the blood-brain barrier: understanding transport mechanisms for improved CNS drug delivery?, AAPS J, 19, 931, 10.1208/s12248-017-0081-9 · DOI · Paper page
- Billington, 2019, Interindividual and regional variability in drug transporter abundance at the human blood-brain barrier measured by quantitative targeted proteomics, Clin Pharmacol Ther, 106, 228, 10.1002/cpt.1373 · DOI
- Meszaros, 2018, Niosomes decorated with dual ligands targeting brain endothelial transporters increase cargo penetration across the blood-brain barrier, Eur J Pharm Sci, 123, 228, 10.1016/j.ejps.2018.07.042 · DOI · Paper page
- Nigam, 2015, What do drug transporters really do?, Nat Rev Drug Discov, 14, 29, 10.1038/nrd4461 · DOI · Paper page
- Lei, 2018, Crystal structure of arginine-bound lysosomal transporter SLC38A9 in the cytosol-open state, Nat Struct Mol Biol, 25, 522, 10.1038/s41594-018-0072-2 · DOI · Paper page
- Patching, 2017, Glucose transporters at the blood-brain barrier: function, regulation and gateways for drug delivery, Mol Neurobiol, 54, 1046, 10.1007/s12035-015-9672-6 · DOI · Paper page
- Spiciarich, 2019, Global health and epilepsy: update and future directions, Curr Neurol Neurosci Rep, 19, 30, 10.1007/s11910-019-0947-6 · DOI
- Loscher, 2013, Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments, Neuropharmacology, 69, 62, 10.1016/j.neuropharm.2012.05.045 · DOI · Paper page
- Moore, 2017, Seizing control of KCC2: a new therapeutic target for epilepsy, Trends Neurosci, 40, 555, 10.1016/j.tins.2017.06.008 · DOI
- Lykke, 2016, The search for NKCC1-selective drugs for the treatment of epilepsy: structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A, Epilepsy Behav., 59, 42, 10.1016/j.yebeh.2016.03.021 · DOI
- Gharaylou, 2019, A preliminary study evaluating the safety and efficacy of bumetanide, an NKCC1 inhibitor, in patients with drug-resistant epilepsy, CNS Drugs, 33, 283, 10.1007/s40263-019-00607-5 · DOI
- Eid, 2016, The glutamate-glutamine cycle in epilepsy, Adv Neurobiol, 13, 351, 10.1007/978-3-319-45096-4_14 · DOI
- Stergachis, 2019, Recurrent SLC1A2 variants cause epilepsy via a dominant negative mechanism, Ann Neurol, 85, 921, 10.1002/ana.25477 · DOI · Paper page
- Zhang, 2019, SLC1A2 mediates refractory temporal lobe epilepsy with an initial precipitating injury by targeting the glutamatergic synapse pathway, IUBMB Life, 71, 213, 10.1002/iub.1956 · DOI
- Mattison, 2018, SLC6A1 variants identified in epilepsy patients reduce gamma-aminobutyric acid transport, Epilepsia, 59, e135, 10.1111/epi.14531 · DOI
- Dikow, 2014, 3p25.3 microdeletion of GABA transporters SLC6A1 and SLC6A11 results in intellectual disability, epilepsy and stereotypic behavior, Am J Med Genet A, 164a, 3061, 10.1002/ajmg.a.36761 · DOI · Paper page
- Hardies, 2015, Recessive mutations in SLC13A5 result in a loss of citrate transport and cause neonatal epilepsy, developmental delay and teeth hypoplasia, Brain, 138, 3238, 10.1093/brain/awv263 · DOI
- Thevenon, 2014, Mutations in SLC13A5 cause autosomal-recessive epileptic encephalopathy with seizure onset in the first days of life, Am J Hum Genet, 95, 113, 10.1016/j.ajhg.2014.06.006 · DOI
- Weeke, 2017, Punctate white matter lesions in full-term infants with neonatal seizures associated with SLC13A5 mutations, Eur J Paediatr Neurol., 21, 396, 10.1016/j.ejpn.2016.11.002 · DOI
- Bhutia, 2017, Plasma membrane Na(+)-coupled citrate transporter (SLC13A5) and neonatal epileptic encephalopathy, Molecules, 22, 378, 10.3390/molecules22030378 · DOI
- Pajor, 2014, Sodium-coupled dicarboxylate and citrate transporters from the SLC13 family, Pflugers Arch, 466, 119, 10.1007/s00424-013-1369-y · DOI · Paper page
- Bainbridge, 2017, Analyses of SLC13A5-epilepsy patients reveal perturbations of TCA cycle, Mol Genet Metab, 121, 314, 10.1016/j.ymgme.2017.06.009 · DOI
- Liang, 2019, Salivary biological biomarkers for Alzheimer's disease, Arch Oral Biol, 105, 5, 10.1016/j.archoralbio.2019.06.004 · DOI
- Liu, 2008, Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease, FEBS Lett, 582, 359, 10.1016/j.febslet.2007.12.035 · DOI · Paper page
- Piert, 1996, Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET, J Nucl Med, 37, 201
- Shah, 2012, The role of glucose transporters in brain disease: diabetes and Alzheimer's disease, Int J Mol Sci, 13, 12629, 10.3390/ijms131012629 · DOI · Paper page
- Hooijmans, 2007, Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice, Brain Res, 1181, 93, 10.1016/j.brainres.2007.08.063 · DOI
- Kim, 2017, Peripheral brain-derived neurotrophic factor levels in Alzheimer's disease and mild cognitive impairment: a comprehensive systematic review and meta-analysis, Mol Neurobiol, 54, 7297, 10.1007/s12035-016-0192-9 · DOI
- Butterfield, 2003, The glutamatergic system and Alzheimer's disease: therapeutic implications, CNS Drugs, 17, 641, 10.2165/00023210-200317090-00004 · DOI · Paper page
- Woltjer, 2010, Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease, J Neuropathol Exp Neurol, 69, 667, 10.1097/NEN.0b013e3181e24adb · DOI · Paper page
- Abdul, 2009, Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling, J Neurosci, 29, 12957, 10.1523/JNEUROSCI.1064-09.2009 · DOI · Paper page
- Kalia, 2015, Parkinson's disease, Lancet, 386, 896, 10.1016/S0140-6736(14)61393-3 · DOI · Paper page
- Stoessl, 2012, Neuroimaging in parkinson's disease: from pathology to diagnosis, Parkinsonism Relat Disord, 18, S55, 10.1016/S1353-8020(11)70019-0 · DOI
- Fu, 2019, Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson's disease induced presynaptic alterations, Neuroimage Clin, 23, 10.1016/j.nicl.2019.101856 · DOI
- McHugh, 2015, The structure and function of the dopamine transporter and its role in CNS diseases, Vitam Horm, 98, 339, 10.1016/bs.vh.2014.12.009 · DOI
- Ikeda, 2019, Dopamine transporter imaging in Parkinson disease: progressive changes and therapeutic modification after anti-parkinsonian medications, Intern Med., 58, 1665, 10.2169/internalmedicine.2489-18 · DOI
- Takahashi, 2019, Quantifying the severity of Parkinson disease by use of dopaminergic neuroimaging, AJR Am J Roentgenol, 1
- Singh, 2018, Insights into the structure, function, and ligand discovery of the large neutral amino acid transporter 1, LAT1, Int J Mol Sci, 19, E1278, 10.3390/ijms19051278 · DOI · Paper page
- Tarlungeanu, 2016, Impaired amino acid transport at the blood brain barrier is a cause of autism spectrum disorder, Cell, 167, 10.1016/j.cell.2016.11.013 · DOI · Paper page
- Liu, 2017, Single nucleotide polymorphisms in SLC19A1 and SLC25A9 are associated with childhood autism spectrum disorder in the chinese HAN population, J Mol Neurosci, 62, 262, 10.1007/s12031-017-0929-6 · doi:10.1007/s12031-017-0929-6
- Maekawa, 2015, Investigation of the fatty acid transporter-encoding genes SLC27A3 and SLC27A4 in autism, Sci Rep, 5, 16239, 10.1038/srep16239 · DOI
- Abrahamsen, 2013, Allosteric modulation of an excitatory amino acid transporter: the subtype-selective inhibitor UCPH-101 exerts sustained inhibition of EAAT1 through an intramonomeric site in the trimerization domain, J Neurosci, 33, 1068, 10.1523/JNEUROSCI.3396-12.2013 · DOI
- Borden, 1994, Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1, Eur J Pharmacol, 269, 219, 10.1016/0922-4106(94)90089-2 · DOI · Paper page
- Lowe, 2009, The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter, Bioorg Med Chem Lett, 19, 2974, 10.1016/j.bmcl.2009.04.035 · DOI
- Anderson, 2017, Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Psychiatry, 4, 595, 10.1016/S2215-0366(17)30236-5 · DOI · Paper page
- Rodrigues, 2017, Tetrabenazine versus deutetrabenazine for Huntington's disease: twins or distant cousins?, Mov Disord Clin Pract, 4, 582, 10.1002/mdc3.12483 · DOI
- Tashima, 2015, Intriguing possibilities and beneficial aspects of transporter-conscious drug design, Bioorg Med Chem, 23, 4119, 10.1016/j.bmc.2015.06.022 · DOI
- Thiele, 2018, Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug, Bioorg Med Chem Lett, 28, 2856, 10.1016/j.bmcl.2018.07.030 · DOI
- Bhunia, 2017, Large amino acid transporter 1 selective liposomes of l-DOPA functionalized amphiphile for combating glioblastoma, Mol Pharm, 14, 3834, 10.1021/acs.molpharmaceut.7b00569 · DOI
- Yu, 2019, Gabapentin increases expression of delta subunit-containing gabaa receptors, EBioMedicine, 42, 203, 10.1016/j.ebiom.2019.03.008 · DOI
- Panebianco, 2018, Gabapentin add-on treatment for drug-resistant focal epilepsy, Cochrane Database Syst Rev, 10
- Dickens, 2013, Transport of gabapentin by LAT1 (SLC7A5), Biochem Pharmacol, 85, 1672, 10.1016/j.bcp.2013.03.022 · DOI
- Kim, 2017, Hallmarks of treatment aspects: Parkinson's disease throughout centuries including L-dopa, Int Rev Neurobiol, 132, 295, 10.1016/bs.irn.2017.01.006 · DOI
- Ostrom, 2018, CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015, Neuro Oncol, 20, iv1, 10.1093/neuonc/noy131 · DOI · Paper page
- Mooney, 2019, Current approaches and challenges in the molecular therapeutic targeting of glioblastoma, World Neurosurg, 129, 90, 10.1016/j.wneu.2019.05.205 · DOI
- Bai, 2017, Structural biology of solute carrier (SLC) membrane transport proteins, Mol Membr Biol, 34, 1, 10.1080/09687688.2018.1448123 · DOI · Paper page
- Chiduza, 2019, LAT1 (SLC7A5) and CD98hc (SLC3A2) complex dynamics revealed by single-particle cryo-EM, Acta Crystallogr D Struct Biol, 75, 660, 10.1107/S2059798319009094 · DOI
- Lee, 2019, Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc, Nat Struct Mol Biol, 26, 510, 10.1038/s41594-019-0237-7 · DOI · Paper page
- Geier, 2013, Structure-based ligand discovery for the large-neutral amino acid transporter 1, LAT-1, Proc Natl Acad Sci USA, 110, 5480, 10.1073/pnas.1218165110 · DOI · Paper page
- Wittwer, 2013, Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling, J Med Chem, 56, 781, 10.1021/jm301302s · DOI · Paper page
Cited by
Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria
Haqqani, A. S., Bélanger, K., & Stanimirovic, D. B. (2024) · Frontiers in Drug Delivery · doi:10.3389/fddev.2024.1360302 · Cited by 153
The barrier and interface mechanisms of the brain barrier, and brain drug delivery
Zhang, S., Gan, L., Cao, F., Wang, H., Gong, P., Ma, C., Ren, L., Lin, Y., & Lin, X. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.09.017 · Cited by 129
Chaves, J. C. S., Dando, S. J., White, A. R., & Oikari, L. E. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166967 · Cited by 62
Zhou, Y., Xu, J., Hou, Y., Bekris, L., Leverenz, J. B., Pieper, A. A., Cummings, J., & Cheng, F. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12350 · Cited by 39
Bertucci, T., Bowles, K. R., Lotz, S., Bheda, S., Qi, L., Farjood, F., Whitton, K., Goderie, S. K., Borden, S., Rossi, A., et al. (2023) · doi:10.1101/2023.07.11.548571 · Cited by 22
Metadata
- Authors
- Hu, C., Tao, L., Cao, X., & Chen, L.
- Venue
- Asian Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 15
- Issue
- 2
- Pages
- 131-144
- ISSN
- 1818-0876 (ISSN-L)
- OpenAlex
- W2984225800
- Cited by
- 157
- References
- 17
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- diamond
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.